FDA granted accelerated approval to TRUTAKNA for adults with IgA nephropathy, based on robust Phase III data showing significant proteinuria reduction and a favorable safety profile. The product will be available within weeks, with a trained sales force and broad payer support.Based on Vera Therape…
FDA granted accelerated approval to TRUTAKNA for adults with IgA nephropathy, based on robust Phase III data showing significant proteinuria reduction and a favorable safety profile. The product will be available within weeks, with a trained sales force and broad payer support.
Based on
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
